Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-11-05

FDA Approved: CONTRAVE EXTENDED-RELEASE — Supplemental Application (Nalpropion Pharmaceuticals LLC)

View source ↗

Summary

FDA approved a supplemental application for CONTRAVE EXTENDED-RELEASE (naltrexone hydrochloride and bupropion hydrochloride) by Nalpropion Pharmaceuticals LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CONTRAVE EXTENDED-RELEASE (Naltrexone hydrochloride and bupropion hydrochloride)

Snippet

SUPPL AP for CONTRAVE EXTENDED-RELEASE (NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE)